L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
Dry skin
- 15min
- May. 2022
- Supported by
Therapeutic classes inducing this adverse event
Antiangiogenic agent, BRAF inhibitor, CTLA4 inhibitor, Chemotherapy, Cyclin-dependent kinase 4/6 inhibitor, EGFR inhibitor, Hormone therapy, KIT inhibitor, MEK inhibitor, PD-1 inhibitor, RAF inhibitor, Radiotherapy, SMO inhibitor, mTOR inhibitor
CTCAE V5.0
Covering <10% bsa and no associated erythema or pruritus
SIMPLIFIED GRADING
No erythema or pruritus
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Covering 10 - 30% BSA and associated with erythema or pruritus; limiting instrumental ADL
SIMPLIFIED GRADING
Erythema or pruritus OR Limiting instrumental ADL
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Covering >30% BSA and associated with pruritus; limiting self care ADL
SIMPLIFIED GRADING
Debilitating pruritis OR Limiting self care ADL
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events